MIRA Pharmaceuticals, Inc. (MIRA)

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

Ticker
MIRA
Exchange
Nasdaq
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$26.89M
52-week range
$0.51 - $1.69

Valuation

Share price
$0.59 (close of Nov 18, 2026)
P/E (TTM)
-1.85x
Price to book
3.93x
Price to free cash flow
-5.56x
Enterprise value
$19.92M
Book value per share
$0.16

Price performance

PeriodChange
1 day-7.81%
5 days-4.84%
1 month-6.35%
3 months-22.37%
6 months-39.80%
Year to date-60.93%
1 year-58.16%
3 years-82.23%
All time-92.05%

Short interest

As of
Oct 30, 2026
Short % of float
0.97%
Shares short
282.32K
Days to cover
1.44
Change since prior report
-19.27%
Source
FINRA consolidated short interest

Profitability and growth

Return on equity
-100.49%
Return on invested capital
-101.44%*
Return on assets
-94.13%
Return on capital employed
-101.44%*

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash flow and balance sheet

Free cash flow yield (TTM)
-18.00%
Current ratio
16.97x
Net debt to EBITDA
0.73x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
EBITDA
-$10.44M
Net income
-$10.44M
Research and development
$1.72M

Income statement by year

Period endNet income
2025-12-31-$10.44M
2024-12-31-$7.85M
2023-12-31-$11.98M
2022-12-31-$7.06M

Margins and returns by year

Period endReturn on equityReturn on capital
2025-12-31-100.49%-101.44%*
2023-12-31-273.92%-194.69%*

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash and debt by year

Period endCash
2025-12-31$11.03M
2024-12-31$2.83M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31-$4.66M$6.31M
2024-12-31-$5.56M$1.92M
2023-12-31-$4.53M$2.55M
2022-12-31-$5.60M$1.30M
2021-12-31-$1.38M-
2020-12-31-$67.99K-

Investor relations

Next earnings report

Next confirmed report
Nov 19, 2026

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-12Sep 2026-
2026-08-12Jun 2026-
2026-05-14Mar 2026-
2025-11-13Sep 2025-
2025-08-14Jun 2025-$0.11
2025-05-14Mar 2025-$0.15
2025-03-28Dec 2024-$0.29
2024-11-12Sep 2024-$0.18

Filings and sources

Company website
mirapharmaceuticals.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Eli Lilly & Co (LLY) · Johnson & Johnson (JNJ) · AbbVie Inc. (ABBV) · Merck & Co., Inc. (MRK) · Novartis AG (NVS) · AstraZeneca plc (AZN) · Amgen Inc (AMGN) · Gilead Sciences, Inc. (GILD)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades